Monoclonal antibodies phage display technology

Humira (EU USA also sold as Trudexa in EU) (adalimumab r (anti-TNF) human monoclonal antibody created using phage display technology Cambridge Antibody Technologies Abbott (USA) Abbott (EU) Rheumatoid arthritis... 

Adalimimab (Humira) is another anti-TNF product for intravenous use. This recombinant human IgGj monoclonal antibody was created by phage display technology and is approved for use in rheumatoid arthritis. 

Human monoclonal antibodies are made either by hybridomas from transgenic mice that have had their mouse antibody genes replaced with human antibody genes, or by a process called phage display. Human monoclonal antibodies end with the suffix -mumab. The first human monoclonal antibody developed through phage display technologies was adalimumab (Humira), which was approved by the FDA to treat several immune system diseases. 

Phage display technology and related techniques such as ribosomal and yeast display systems form the basis of modern monoclonal antibody production.Bacteriophages are vimses that infect a range of bacteria. They only have 11 genes. Figure 27.20 shows a schematic... 

Affinity selection is by far the most important application of phage display (for practical reviews, see [4, 5]). Libraries of phage-displayed peptides are now commonly used to select peptides that bind to receptors or enzymes of therapeutic interest. The technology is also very powerful for the discovery of new monoclonal antibodies from collections of phages displayed single chain Fv or Fab fragments. 

There are currently 18 monoclonal antibodies which have been licensed for therapeutic use and this therapeutic category is expanding rapidly. The majority of these antibodies have been produced by recombinant DNA technology such as the phage display system but there are three which are produced by the more old-fashioned murine antibody technology produced in hybridomas. There is currently quite a number of Fab fragments in clinical trials. 

---